慢加急性肝衰竭诊治的研究进展  

Research progress for diagnosis and treatment of acute-on-chronic liver failure

作　　者：姚雅极 邹圣强 周建国[1] 谭友文 庄涛 胡佳民 严孝馨 江竹月 陈丽 刘津含 YAO Yaji;ZOU Shengqiang;ZHOU Jianguo;TAN Youwen;ZHUANG Tao;HU Jiamin;YAN Xiaoxin;JIANG Zhuyue(The Affiliated Third Hospital of Jiangsu University,Zhenjiang 212005,China;School of Medicine,Jiangsu University,Zhenjiang 212013,China)

机构地区：[1]江苏大学附属镇江三院(江苏大学肝研所),镇江212005 [2]江苏大学医学院,镇江212013

出　　处：《中华灾害救援医学》2019年第8期469-474,共6页Chinese Journal of Disaster Medicine

基　　金：中国肝炎防治基金（WBEXJS2018001）;镇江市重点研发计划（社会发展）项目(SH2018028)

摘　　要：慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)是由于慢性肝病发生急性恶化,导致肝脏衰竭的临床综合征,是肝衰竭中最常见的类型,病死率极高,预后极差.目前尚无彻底有效的治疗手段,常规采用的疗法有抗病毒治疗、人工肝治疗等.近年来,随着国内外医疗技术的不断发展,在治疗ACLF上取得了一定的进展,如人工肝支持系统、间充质干细胞移植等方面的技术,从而明显降低了患者的死亡率.本文重点介绍了ACLF的概念、病因、诱因、发病机制及临床流行病,总结了ACLF的最新治疗方法,并对目前ACLF治疗所存在的问题进行了总结和展望.Acute-on-chronic liver failure(ACLF),a most common type of hepatic failure with a dismal prognosis and high mortality,is a clinical syndrome of liver failure by the chronic liver disease acute exacerbations.At present,there is no completely effective method for treatment of ACLF.Routine therapies mainly include antiviral treatment and artificial liver support.In recent years,with the development of medical technology,the therapy of ACLF has made some progress,including artificial liver support system,mesenchymal stem cell transplantation,which can reduce the death rate significantly.This review aims to introduce the definition,pathogenesis,inducement,clinical epidemic and summarize new method for treatment of ACLF.And the current problems against treatment for ACLF are summarized and prospected.

关 键 词：肝衰竭 慢加急 研究进展 

分 类 号：R575.3[医药卫生—消化系统]